About Market Research Forecast

MR Forecast provides premium market intelligence on deep technologies that can cause a high level of disruption in the market within the next few years. When it comes to doing market viability analyses for technologies at very early phases of development, MR Forecast is second to none. What sets us apart is our set of market estimates based on secondary research data, which in turn gets validated through primary research by key companies in the target market and other stakeholders. It only covers technologies pertaining to Healthcare, IT, big data analysis, block chain technology, Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Energy & Power, Automobile, Agriculture, Electronics, Chemical & Materials, Machinery & Equipment's, Consumer Goods, and many others at MR Forecast. Market: The market section introduces the industry to readers, including an overview, business dynamics, competitive benchmarking, and firms' profiles. This enables readers to make decisions on market entry, expansion, and exit in certain nations, regions, or worldwide. Application: We give painstaking attention to the study of every product and technology, along with its use case and user categories, under our research solutions. From here on, the process delivers accurate market estimates and forecasts apart from the best and most meaningful insights.

Products generically come under this phrase and may imply any number of goods, components, materials, technology, or any combination thereof. Any business that wants to push an innovative agenda needs data on product definitions, pricing analysis, benchmarking and roadmaps on technology, demand analysis, and patents. Our research papers contain all that and much more in a depth that makes them incredibly actionable. Products broadly encompass a wide range of goods, components, materials, technologies, or any combination thereof. For businesses aiming to advance an innovative agenda, access to comprehensive data on product definitions, pricing analysis, benchmarking, technological roadmaps, demand analysis, and patents is essential. Our research papers provide in-depth insights into these areas and more, equipping organizations with actionable information that can drive strategic decision-making and enhance competitive positioning in the market.

About Market Research Forecast

Viral Vaccines Market

Viral Vaccines Market Unlocking Growth Opportunities: Analysis and Forecast 2025-2033

Viral Vaccines Market by Form (Liquid, Lyophilized), by Container Format (Vials, Prefilled Syringes), by Biosafety Level Type (Biosafety Level 1, Biosafety Level 2, Biosafety Level 3, Biosafety Level 4), by North America (U.S., Canada) Forecast 2026-2034

Aug 8 2025

Base Year: 2025

180 Pages

Viral Vaccines Market Unlocking Growth Opportunities: Analysis and Forecast 2025-2033

Key Insights

The size of the Viral Vaccines Market was valued at USD 122.6 USD Billion in 2023 and is projected to reach USD 165.73 USD Billion by 2032, with an expected CAGR of 4.4% during the forecast period. Viral vaccines are biological preparations designed to provide immunity against specific viral infections. They work by stimulating the body's immune system to recognize and combat viruses. There are several types, including inactivated (killed) vaccines, which use viruses that have been killed or inactivated; live attenuated vaccines, which contain weakened forms of the virus; and subunit, recombinant, or conjugate vaccines, which include only parts of the virus to elicit an immune response. Features of viral vaccines include their ability to prevent disease, reduce transmission, and sometimes provide long-term immunity. Applications range from preventing common illnesses like influenza and measles to protecting against more severe conditions such as hepatitis and human papillomavirus (HPV).

Viral Vaccines Market Trends

Viral Vaccines Market Market Size and Forecast (2024-2030) — Viral Vaccines Market Company Market Share

The Viral Vaccines Market is witnessing significant trends, including:

Emergence of Novel Viral Threats: The COVID-19 pandemic has highlighted the need for effective viral vaccines to combat novel and emerging viral threats.
Technological Advancements: Advancements in vaccine delivery systems, such as mRNA vaccines and viral vector-based vaccines, are enhancing vaccine efficacy and safety.
Increasing Healthcare Expenditure: Growing healthcare spending by governments and private organizations supports research and development of viral vaccines.
Rising Awareness: Public health campaigns and awareness programs are educating individuals about the importance of viral vaccination.
Regulatory Approvals: Regulatory agencies are expediting the approval process for new and innovative viral vaccines.

Driving Forces: What's Propelling the Viral Vaccines Market

The Viral Vaccines Market is experiencing robust growth, fueled by a confluence of factors impacting global health and economic landscapes. These driving forces are multifaceted and interconnected, creating a sustained demand for innovative and effective viral vaccines.

Persisting and Evolving Viral Threats: The ongoing prevalence of established viral diseases like influenza, hepatitis B and C, and HPV, coupled with the emergence of novel viral infections (e.g., Zika, COVID-19), underscores the critical need for preventative vaccination strategies. This persistent threat necessitates continuous vaccine research and development.
Strengthened Public Health Initiatives: Governments worldwide are increasingly prioritizing vaccination programs as a cornerstone of public health infrastructure. This commitment translates into substantial investments in vaccine procurement, distribution networks, and public awareness campaigns, directly impacting market growth.
Accelerated Technological Advancements: The field of vaccinology is witnessing rapid advancements, including mRNA technology, novel adjuvant systems, and improved delivery methods (e.g., intranasal vaccines). These innovations are leading to more effective, safer, and easier-to-administer vaccines, expanding market potential.
Expanding Access to Healthcare in Emerging Markets: Rising disposable incomes and improved healthcare infrastructure in developing economies are driving increased demand for preventative healthcare services, including vaccinations. This expanding market represents significant growth opportunities for vaccine manufacturers.
Globalization and Increased Travel: The interconnected nature of the global community, facilitated by increased international travel and trade, significantly increases the risk of rapid viral spread. This heightened risk underscores the importance of widespread vaccination to mitigate potential pandemics and outbreaks.

Challenges and Restraints in Viral Vaccines Market

Despite the significant market potential, the Viral Vaccines Market faces considerable challenges that hinder widespread access and adoption. Addressing these obstacles is crucial for maximizing the impact of vaccination programs and protecting global public health.

Vaccine Hesitancy and Misinformation: The spread of misinformation and vaccine hesitancy poses a significant threat to vaccination coverage rates. Combating these challenges requires effective public health communication strategies and addressing concerns about vaccine safety and efficacy transparently.
Complex Cold Chain Management: Many viral vaccines require stringent cold chain storage and transportation, posing logistical challenges, particularly in resource-limited settings. This necessitates investment in robust cold chain infrastructure and innovative vaccine formulations that require less stringent storage conditions.
High Development and Manufacturing Costs: The research, development, manufacturing, and distribution of viral vaccines can be expensive, creating access barriers, particularly in low- and middle-income countries. Innovative financing mechanisms and collaborations are needed to ensure equitable access.
Evolving Viral Strains and Antigenic Drift: The ability of viruses to mutate and evolve rapidly necessitates continuous vaccine adaptation and development. This requires ongoing research and surveillance to track viral strains and develop updated vaccines.
Regulatory Hurdles and Approvals: Navigating the complex regulatory landscape for vaccine approval and licensing can be time-consuming and costly, potentially delaying the market entry of innovative vaccines. Streamlining regulatory processes can help accelerate vaccine development and deployment.

Key Region or Country & Segment to Dominate the Market

Key Regions:

North America: Advanced healthcare systems, high disposable income, and government initiatives drive market growth.
Europe: Strong healthcare infrastructure, public vaccination programs, and aging population support market expansion.
Asia-Pacific: Rising healthcare expenditure, increasing prevalence of viral diseases, and government vaccination campaigns contribute to market growth.

Dominant Segment:

Liquid Form: Liquid vaccines offer ease of administration, flexibility in dosage, and stability during storage.

Growth Catalysts in Viral Vaccines Industry

Growth catalysts for the Viral Vaccines Industry include:

Advancements in Vaccine Delivery Systems: Innovations in vaccine delivery systems, such as microneedles and transdermal patches, enhance vaccine effectiveness and reduce pain.
Emphasis on Personalized Medicine: Tailoring vaccines to individual immune responses optimizes vaccine efficacy and minimizes adverse effects.
Government Support for Research and Development: Government funding and incentives support the development of new and improved viral vaccines.
Consolidation and Collaboration: Partnerships and acquisitions among vaccine manufacturers strengthen market positions and advance vaccine development.

Market Segmentation: Viral Vaccines Analysis

The Viral Vaccines Market is segmented based on:

Type: Influenza vaccines, hepatitis vaccines, HPV vaccines, and other viral vaccines
Form: Liquid and lyophilized
Container Format: Vials and prefilled syringes
Biosafety Level Type: Biosafety Level 1, Biosafety Level 2, Biosafety Level 3, and Biosafety Level 4
Distribution Channel: Hospitals, clinics, pharmacies, and online platforms

Leading Players in the Viral Vaccines Market

Prominent players in the Viral Vaccines Market include:

Significant Developments in Viral Vaccines Sector

Notable recent developments in the Viral Vaccines Sector include:

March 2023: Novavax received authorization from the U.S. FDA for its COVID-19 vaccine, Nuvaxovid.
February 2023: Moderna announced positive topline results from its phase 2 study of its mRNA-based RSV vaccine candidate.
December 2022: Serum Institute of India launched a monovalent rotavirus vaccine, ROTAVAC 5D, specifically tailored for the Indian market.
November 2022: GlaxoSmithKline (GSK) received regulatory approval for its shingles vaccine, Shingrix, in China.
October 2022: Pfizer announced the initiation of a phase 3 trial to evaluate its mRNA-based influenza vaccine candidate.

Geographic Coverage of Viral Vaccines Market

Higher Coverage

Lower Coverage

No Coverage

Viral Vaccines Market REPORT HIGHLIGHTS

Aspects	Details
Study Period	2020-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2020-2025
Growth Rate	CAGR of 4.4% from 2020-2034
Segmentation	By Form Liquid Lyophilized By Container Format Vials Prefilled Syringes By Biosafety Level Type Biosafety Level 1 Biosafety Level 2 Biosafety Level 3 Biosafety Level 4 By Geography North America U.S. Canada

1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
- 2.1. Introduction
3. Market Dynamics
- 3.1. Introduction
- - 3.2. Market Drivers
  - - 3.2.1. Increasing Incidence of Viral Infections to Propel Market Growth
- - 3.3. Market Restrains
  - - 3.3.1. Stringent Pricing Control to Hinder Market Growth
- - 3.4. Market Trends
  - - 3.4.1. Gradual Shift from Vials to Prefilled Syringes to Determine Market Growth
4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
5. Global Viral Vaccines Market Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Form
  - 5.1.1. Liquid
  - 5.1.2. Lyophilized
- 5.2. Market Analysis, Insights and Forecast - by Container Format
  - 5.2.1. Vials
  - 5.2.2. Prefilled Syringes
- 5.3. Market Analysis, Insights and Forecast - by Biosafety Level Type
  - 5.3.1. Biosafety Level 1
  - 5.3.2. Biosafety Level 2
  - 5.3.3. Biosafety Level 3
  - 5.3.4. Biosafety Level 4
- 5.4. Market Analysis, Insights and Forecast - by Region
  - 5.4.1. North America
6. Competitive Analysis
- 6.1. Global Market Share Analysis 2025
- - 6.2. Company Profiles
  - - 6.2.1 Merck & Co. Inc. (U.S.)
      6.2.1.1. Overview
      6.2.1.2. Products
      6.2.1.3. SWOT Analysis
      6.2.1.4. Recent Developments
      6.2.1.5. Financials (Based on Availability)
    - 6.2.2 GSK plc (U.K.)
      6.2.2.1. Overview
      6.2.2.2. Products
      6.2.2.3. SWOT Analysis
      6.2.2.4. Recent Developments
      6.2.2.5. Financials (Based on Availability)
    - 6.2.3 Sanofi (France)
      6.2.3.1. Overview
      6.2.3.2. Products
      6.2.3.3. SWOT Analysis
      6.2.3.4. Recent Developments
      6.2.3.5. Financials (Based on Availability)
    - 6.2.4 Pfizer Inc. (U.S.)
      6.2.4.1. Overview
      6.2.4.2. Products
      6.2.4.3. SWOT Analysis
      6.2.4.4. Recent Developments
      6.2.4.5. Financials (Based on Availability)
    - 6.2.5 SEQIRUS (CSL Limited) (Australia)
      6.2.5.1. Overview
      6.2.5.2. Products
      6.2.5.3. SWOT Analysis
      6.2.5.4. Recent Developments
      6.2.5.5. Financials (Based on Availability)
    - 6.2.6 Moderna Inc. (U.S.)
      6.2.6.1. Overview
      6.2.6.2. Products
      6.2.6.3. SWOT Analysis
      6.2.6.4. Recent Developments
      6.2.6.5. Financials (Based on Availability)
    - 6.2.7 AstraZeneca (U.K.)
      6.2.7.1. Overview
      6.2.7.2. Products
      6.2.7.3. SWOT Analysis
      6.2.7.4. Recent Developments
      6.2.7.5. Financials (Based on Availability)
    - 6.2.8 Johnson & Johnson Services Inc. (U.S.)
      6.2.8.1. Overview
      6.2.8.2. Products
      6.2.8.3. SWOT Analysis
      6.2.8.4. Recent Developments
      6.2.8.5. Financials (Based on Availability)
    - 6.2.9 Novavax (U.S.)
      6.2.9.1. Overview
      6.2.9.2. Products
      6.2.9.3. SWOT Analysis
      6.2.9.4. Recent Developments
      6.2.9.5. Financials (Based on Availability)
    - 6.2.10 Dynavax Technologies (U.S.)
      6.2.10.1. Overview
      6.2.10.2. Products
      6.2.10.3. SWOT Analysis
      6.2.10.4. Recent Developments
      6.2.10.5. Financials (Based on Availability)

List of Figures

Figure 1: Global Viral Vaccines Market Revenue Breakdown (USD Billion, %) by Region 2025 & 2033
Figure 2: Global Viral Vaccines Market Volume Breakdown (No.of doses, %) by Region 2025 & 2033
Figure 3: North America Viral Vaccines Market Revenue (USD Billion), by Form 2025 & 2033
Figure 4: North America Viral Vaccines Market Volume (No.of doses), by Form 2025 & 2033
Figure 5: North America Viral Vaccines Market Revenue Share (%), by Form 2025 & 2033
Figure 6: North America Viral Vaccines Market Volume Share (%), by Form 2025 & 2033
Figure 7: North America Viral Vaccines Market Revenue (USD Billion), by Container Format 2025 & 2033
Figure 8: North America Viral Vaccines Market Volume (No.of doses), by Container Format 2025 & 2033
Figure 9: North America Viral Vaccines Market Revenue Share (%), by Container Format 2025 & 2033
Figure 10: North America Viral Vaccines Market Volume Share (%), by Container Format 2025 & 2033
Figure 11: North America Viral Vaccines Market Revenue (USD Billion), by Biosafety Level Type 2025 & 2033
Figure 12: North America Viral Vaccines Market Volume (No.of doses), by Biosafety Level Type 2025 & 2033
Figure 13: North America Viral Vaccines Market Revenue Share (%), by Biosafety Level Type 2025 & 2033
Figure 14: North America Viral Vaccines Market Volume Share (%), by Biosafety Level Type 2025 & 2033
Figure 15: North America Viral Vaccines Market Revenue (USD Billion), by Country 2025 & 2033
Figure 16: North America Viral Vaccines Market Volume (No.of doses), by Country 2025 & 2033
Figure 17: North America Viral Vaccines Market Revenue Share (%), by Country 2025 & 2033
Figure 18: North America Viral Vaccines Market Volume Share (%), by Country 2025 & 2033

List of Tables

Table 1: Global Viral Vaccines Market Revenue USD Billion Forecast, by Form 2020 & 2033
Table 2: Global Viral Vaccines Market Volume No.of doses Forecast, by Form 2020 & 2033
Table 3: Global Viral Vaccines Market Revenue USD Billion Forecast, by Container Format 2020 & 2033
Table 4: Global Viral Vaccines Market Volume No.of doses Forecast, by Container Format 2020 & 2033
Table 5: Global Viral Vaccines Market Revenue USD Billion Forecast, by Biosafety Level Type 2020 & 2033
Table 6: Global Viral Vaccines Market Volume No.of doses Forecast, by Biosafety Level Type 2020 & 2033
Table 7: Global Viral Vaccines Market Revenue USD Billion Forecast, by Region 2020 & 2033
Table 8: Global Viral Vaccines Market Volume No.of doses Forecast, by Region 2020 & 2033
Table 9: Global Viral Vaccines Market Revenue USD Billion Forecast, by Form 2020 & 2033
Table 10: Global Viral Vaccines Market Volume No.of doses Forecast, by Form 2020 & 2033
Table 11: Global Viral Vaccines Market Revenue USD Billion Forecast, by Container Format 2020 & 2033
Table 12: Global Viral Vaccines Market Volume No.of doses Forecast, by Container Format 2020 & 2033
Table 13: Global Viral Vaccines Market Revenue USD Billion Forecast, by Biosafety Level Type 2020 & 2033
Table 14: Global Viral Vaccines Market Volume No.of doses Forecast, by Biosafety Level Type 2020 & 2033
Table 15: Global Viral Vaccines Market Revenue USD Billion Forecast, by Country 2020 & 2033
Table 16: Global Viral Vaccines Market Volume No.of doses Forecast, by Country 2020 & 2033
Table 17: U.S. Viral Vaccines Market Revenue (USD Billion) Forecast, by Application 2020 & 2033
Table 18: U.S. Viral Vaccines Market Volume (No.of doses) Forecast, by Application 2020 & 2033
Table 19: Canada Viral Vaccines Market Revenue (USD Billion) Forecast, by Application 2020 & 2033
Table 20: Canada Viral Vaccines Market Volume (No.of doses) Forecast, by Application 2020 & 2033

Methodology

Step 1 - Identification of Relevant Samples Size from Population Database

Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)

Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segments, product, and application.

Note*: In applicable scenarios

Step 3 - Data Sources

Primary Research

Web Analytics
Survey Reports
Research Institute
Latest Research Reports
Opinion Leaders

Secondary Research

Annual Reports
White Paper
Latest Press Release
Industry Association
Paid Database
Investor Presentations

Step 4 - Data Triangulation

Involves using different sources of information in order to increase the validity of a study

These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.

Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.

During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence

Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.

Frequently Asked Questions

1. What is the projected Compound Annual Growth Rate (CAGR) of the Viral Vaccines Market?

The projected CAGR is approximately 4.4%.

2. Which companies are prominent players in the Viral Vaccines Market?

Key companies in the market include Merck & Co., Inc. (U.S.), GSK plc (U.K.), Sanofi (France), Pfizer Inc. (U.S.), SEQIRUS (CSL Limited) (Australia), Moderna, Inc. (U.S.), AstraZeneca (U.K.), Johnson & Johnson Services, Inc. (U.S.), Novavax (U.S.), Dynavax Technologies (U.S.).

3. What are the main segments of the Viral Vaccines Market?

The market segments include Form, Container Format, Biosafety Level Type.

4. Can you provide details about the market size?

The market size is estimated to be USD 122.6 USD Billion as of 2022.

5. What are some drivers contributing to market growth?

Increasing Incidence of Viral Infections to Propel Market Growth.

6. What are the notable trends driving market growth?

Gradual Shift from Vials to Prefilled Syringes to Determine Market Growth.

7. Are there any restraints impacting market growth?

Stringent Pricing Control to Hinder Market Growth.

8. Can you provide examples of recent developments in the market?

July 2023: GSK plc received authorization for Arexvy from the Medicines and Healthcare Products Regulatory Agency (MHRA).

9. What pricing options are available for accessing the report?

Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4850, USD 5850, and USD 6850 respectively.

10. Is the market size provided in terms of value or volume?

The market size is provided in terms of value, measured in USD Billion and volume, measured in No.of doses.

11. Are there any specific market keywords associated with the report?

Yes, the market keyword associated with the report is "Viral Vaccines Market," which aids in identifying and referencing the specific market segment covered.

12. How do I determine which pricing option suits my needs best?

The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.

13. Are there any additional resources or data provided in the Viral Vaccines Market report?

While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.

14. How can I stay updated on further developments or reports in the Viral Vaccines Market?

To stay informed about further developments, trends, and reports in the Viral Vaccines Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.

Get Free Sample

Pre Order Enquiry Request discount

Pricing

Related Reports

U.S. Vaccines Market Decade Long Trends, Analysis and Forecast 2025-2033

Influenza Vaccine Market Insightful Analysis: Trends, Competitor Dynamics, and Opportunities 2025-2033

Vaccines Market Soars to USD Billion , witnessing a CAGR of 6.6 during the forecast period 2025-2033

Recombinant Vaccines Market Charting Growth Trajectories: Analysis and Forecasts 2025-2033

Viral Vaccines Report Probes the XXX million Size, Share, Growth Report and Future Analysis by 2033

Tailored for you

In-depth Analysis Tailored to Specified Regions or Segments
Company Profiles Customized to User Preferences
Comprehensive Insights Focused on Specific Segments or Regions
Customized Evaluation of Competitive Landscape to Meet Your Needs
Tailored Customization to Address Other Specific Requirements

Ask for customization

The response was good, and I got what I was looking for as far as the report. Thank you for that.

Erik Perison

US TPS Business Development Manager at Thermon

As requested- presale engagement was good, your perseverance, support and prompt responses were noted. Your follow up with vm’s were much appreciated. Happy with the final report and post sales by your team.

Shankar Godavarti

Global Product, Quality & Strategy Executive- Principal Innovator at Donaldson

I have received the report already. Thanks you for your help.it has been a pleasure working with you. Thank you againg for a good quality report